Articles Posted in merger remedies

FTC Says No More Divestitures of Complex Pipeline Products to Resolve Future Competition Concerns in Pharmaceutical Mergers
Doyle, Barlow & Mazard PLLC

On February 2, 2018, Bruce Hoffman, the Federal Trade Commission’s (“FTC”) acting Director of the Bureau of Competition, announced at the Global Competition Review Seventh Annual Antitrust Law Leaders Forum that the FTC will no longer accept divestitures of inhalant and injectable pipeline drugs in pharmaceutical mergers.  Historically, the FTC had accepted divestiture of pipeline…

Continue reading ›
Enforcement over Regulation: New Antitrust Cop Sets High Bar for Behavioral Remedies
Doyle, Barlow & Mazard PLLC

On November 16, 2017, Makan Delrahim, recently confirmed as Assistant Attorney General for the Antitrust Division of the U.S. Department of Justice (“DOJ”), delivered a speech on the relationship between antitrust as law enforcement and his goal of reducing regulation. Delrahim explained that effective antitrust enforcement lessens the need for market regulations and that behavioral…

Continue reading ›
DOJ Approves Charter’s Acquisition of TWC With Behavioral Conditions
Doyle, Barlow & Mazard PLLC

On April 25, 2016, the DOJ entered into settlement agreement approving Charter Communications, Inc.’s (“Charter”) acquisition of Time Warner Cable Inc. (“TWC”) and its related acquisition of Bright House Networks, LLC to create New Charter as long as the parties agreed to certain behavioral conditions. DOJ’s Vertical Concerns Related to the Creation of New Charter…

Continue reading ›
Aerial view of Washington DC cityscape from Arlington Virginia USA.

Contact Us

Fill out the form or call us at (202) 589-1834 to schedule your consultation.